Journal of Clinical Endocrinology & Metabolism, Vol 67, 1054-1059, Copyright © 1988 by Endocrine Society

ARTICLES

Alpha 2-adrenoceptor blockade does not enhance glucose-induced insulin release in normal subjects or patients with noninsulin-dependent diabetes

CG Ostenson, J Pigon, JC Doxey and S Efendic
Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden.

Studies with phentolamine, an alpha-adrenergic antagonist, in normal subjects and diabetic patients have indicated that insulin secretion may be inhibited by tonic alpha-adrenergic stimulation of pancreatic B- cells. We evaluated, with the use of the highly selective alpha 2- adrenoceptor antagonist idazoxan, the role of alpha 2-adrenergic receptors in the regulation of glucose-induced insulin secretion. A glucose infusion test (GIT) was performed after the administration of idazoxan or placebo in normal men (n = 15) and men with noninsulin- dependent diabetes mellitus (n = 6). The normal men were divided into two groups on the basis of high (n = 8) and low (n = 7) insulin responses to prior GITs. The blood glucose and plasma insulin and C- peptide responses to the GIT were similar after idazoxan (40 mg, orally) or placebo treatment in all three groups, although the responses differed among the groups. In the diabetic group iv administration of idazoxan 20 min before the GIT did not alter the insulin response to the GIT. We conclude that alpha 2-adrenergic blockade does not affect glucose-induced insulin secretion in normal men, nor does it improve the impaired first phase of insulin secretion in low insulin responders and noninsulin-dependent diabetes mellitus patients. Phentolamine probably stimulates insulin secretion by a mechanism not involving alpha 2-adrenergic receptors directly.

This article has been cited by other articles:

				J.-C. Henquin Pathways in Beta-Cell Stimulus-Secretion Coupling as Targets for Therapeutic Insulin Secretagogues Diabetes, December 1, 2004; 53(suppl_3): S48 - S58. [Abstract] [Full Text] [PDF]

				C. Bleck, A. Wienbergen, and I. Rustenbeck Glucose Dependence of Imidazoline-Induced Insulin Secretion: Different Characteristics of Two ATP-Sensitive K+ Channel-Blocking Compounds Diabetes, December 1, 2004; 53(suppl_3): S135 - S139. [Abstract] [Full Text] [PDF]

				B. Davani, N. Portwood, G. Bryzgalova, M. K. Reimer, T. Heiden, C.-G. Ostenson, S. Okret, B. Ahren, S. Efendic, and A. Khan Aged Transgenic Mice With Increased Glucocorticoid Sensitivity in Pancreatic {beta}-Cells Develop Diabetes Diabetes, February 1, 2004; 53(90001): S51 - 59. [Abstract] [Full Text]

				S. Efendic, A. M. Efanov, P.-O. Berggren, and S. V. Zaitsev Two Generations of Insulinotropic Imidazoline Compounds Diabetes, December 1, 2002; 51(90003): S448 - 454. [Abstract] [Full Text] [PDF]

				T. Leon-Quinto, C. Magnan, and B. Portha Altered Activity of the Autonomous Nervous System as a Determinant of the Impaired {beta}-Cell Secretory Response after Protein-Energy Restriction in the Rat Endocrinology, August 1, 1998; 139(8): 3382 - 3389. [Abstract] [Full Text] [PDF]

				A. Natali, A. Gastaldelli, A. Q. Galvan, A. M. Sironi, D. Ciociaro, G. Sanna, P. Rosenzweig, and E. Ferrannini Effects of acute alpha 2-blockade on insulin action and secretion in humans Am J Physiol Endocrinol Metab, January 1, 1998; 274(1): E57 - E64. [Abstract] [Full Text] [PDF]